1. Metabolic Enzyme/Protease Apoptosis Autophagy NF-κB MAPK/ERK Pathway
  2. Endogenous Metabolite Apoptosis Autophagy Keap1-Nrf2 p38 MAPK Caspase
  3. Madecassoside

Madecassoside  (Synonyms: Asiaticoside A)

Cat. No.: HY-N0568 Purity: 99.86%
COA Handling Instructions

Madecassoside is a pentacyclic triterpene isolated from Centella asiatica and has anti-inflammatory properties. Antioxidant and anti-aging effects. Madecassoside is a pentacyclic triterpene isolated from Centella asiatica. Madecassoside is orally active and has inhibitory properties against inflammation, oxidation, apoptosis and autophagy. Madecassosid inhibits activities of p38 MAPK and NF-kB[5][6], exhibits an anti-apopototic property, activates Nrf2 expression to reduce the neurotoxicity. Madecassoside can be used in endocrine diseases, cardiovascular diseases, skin diseases and other diseases.

For research use only. We do not sell to patients.

Madecassoside Chemical Structure

Madecassoside Chemical Structure

CAS No. : 34540-22-2

Size Price Stock Quantity
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
USD 73 In-stock
Solution
10 mM * 1 mL in DMSO USD 73 In-stock
Solid
5 mg USD 42 In-stock
10 mg USD 66 In-stock
50 mg USD 198 In-stock
100 mg USD 317 In-stock
200 mg USD 515 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Madecassoside is a pentacyclic triterpene isolated from Centella asiatica and has anti-inflammatory properties. Antioxidant and anti-aging effects. Madecassoside is a pentacyclic triterpene isolated from Centella asiatica. Madecassoside is orally active and has inhibitory properties against inflammation, oxidation, apoptosis and autophagy. Madecassosid inhibits activities of p38 MAPK and NF-kB[5][6], exhibits an anti-apopototic property, activates Nrf2 expression to reduce the neurotoxicity[10]. Madecassoside can be used in endocrine diseases, cardiovascular diseases, skin diseases and other diseases.

In Vitro

Madecassosid (30, 100 μmol/L, 12 h) increases cell viability of oxidative injuried human umbilical vein endothelial cells (HUVECs)[5].
Madecassosid (10-100 μmol/L, 12 h) inhibits phosphorylation of p38 MAPK and activaty of Caspase-3, and therefore exhibits an antiapoptotic activity[5].
Madecassosid (10-100 μg/L) exhibits anxioxidative activity against melanocyte dendtrites retraction, maintaining mitochondrial membrane potential and Ca2+ homeostasis[7]< /sup>.
Madecassosid (30 μM) improves
Insulin secretion by increasing expressions of p-IRS1, Akt and p-Akt under glucotoxic conditions[8].
Madecassosid (10 μM, 24 h) prevents inflammation and autophagy of neuronal cells induced by Aβ25–35 through the class III PI3K/Beclin-1/Bcl-2 pathway[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[5]

Cell Line: HUVECs
Concentration: 10, 30, 100 μmol/L
Incubation Time: 12 h
Result: Increased cell viability to 68.9% and 78.3%, with concentration of 30 and 100 μmol/L, respectively.

Western Blot Analysis[5]

Cell Line: HUVECs
Concentration: 10, 30, 100 μmol/L
Incubation Time: 12 h
Result: Inhibited phosphorylation in p38 MAPK.
In Vivo

Madecassosid (6, 12, 24 mg/kg, i.v.) resolves neurological deficit and ameliorates neuronal apoptosis after focal cerebral ischemia reperfusion[6].
Madecassosid (6, 12, 24 mg/kg, i.v) inhibits activity of NF-kB and so prevents the brain injury[6].
Madecassosid (120 mg/kg, i.g.) reduces LPS-induced neurotoxicity and enhances heme oxygenase proteins via upregulation of Nrf2 in LPS-stimulated neurotoxicity[10].
Madecassosid (10-40 mg/kg,p.o.) ameliorates oxidative damage and imflammation after bleomycin (BLM) instillation, inhibits TGF-β1 overexpression and collagen synthesis, improves collagen degradation[11].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Focal cerebral ischemia reperfusion injury in Sprague Dawley rats[6]
Dosage: 6, 12, 24 mg/kg
Administration: Intravenous injection
Result: Reduced neurological deficit, infarct area, brain damage and neuronal apoptosis.
Animal Model: Lipopolysaccharide-induced neurotoxicity in Sprague-Dawley rats[10]
Dosage: 30-120 mg/kg for 14 days
Administration: Intraperitoneal injection
Result: Reduced LPS-induced cognitive impairment and imflammatory cytokine, promoted Nrf2 pathway at concentration of 120 mg/kg.
Clinical Trial
Molecular Weight

975.12

Formula

C48H78O20

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(C1(CCC(C)C2C)C2C3=CCC4C(C)(CC(O)C5C4(CC(O)C(O)C5(C)CO)C)C3(C)CC1)OC(C(C(O)C6O)O)OC6COC(C(C(O)C7OC(OC(C)C(O)C8O)C8O)O)OC7CO

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (102.55 mM; Need ultrasonic)

H2O : 33.33 mg/mL (34.18 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.0255 mL 5.1276 mL 10.2551 mL
5 mM 0.2051 mL 1.0255 mL 2.0510 mL
10 mM 0.1026 mL 0.5128 mL 1.0255 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  PBS

    Solubility: 25 mg/mL (25.64 mM); Clear solution; Need ultrasonic

  • 2.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (2.56 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (2.56 mM); Clear solution

  • 4.

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (2.56 mM); Clear solution

*All of the co-solvents are available by MedChemExpress (MCE).
Purity & Documentation

Purity: 99.86%

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Madecassoside
Cat. No.:
HY-N0568
Quantity:
MCE Japan Authorized Agent: